SUBSCRIBE

Breaking News on Biopharmaceutical Development & Manufacturing

Headlines > June 2017

« Previous month Next month »

Patheon to spend $45m on manufacturing plants ahead of Thermo takeover

30-Jun-2017 - Patheon NV has announced it will spend $45m to expand and enhance its manufacturing network citing customer demand for more reliable, flexible and cost-efficient supply chains.

Coherus terminates 51 jobs post FDA rejection

30-Jun-2017 - Coherus Biosciences has submitted a US Securities and Exchange Commission filing , announcing it will eliminate 51 jobs to reduce operating costs.

Dispatches from BioPharma Expo, Japan

Lonza expands in Asia: 8,000L single-use in Singapore, regenerative meds in Japan

30-Jun-2017 - Lonza will install four 2,000L single-use bioreactors at its Singapore facility to cater for growing demand for small to mid-volume biologics production.

Pfizer starts work on Missouri biotherapeutics R&D hub

28-Jun-2017 - Pfizer is building a $200m (€179m) R&D centre in Chesterfield, Missouri at which it will consolidate biotherapeutics process development operations in the region.

Dispatches from Interphex Japan

Tokyo drift? Large molecule R&D shortfall threat to Japanese pharma, says Chugai

28-Jun-2017 - A failure to embrace biologics R&D has restricted Japanese pharma’s global growth, says CEO of Roche subsidiary Chugai Pharmaceuticals.

Cloud-based platform for cell therapies to meet increased production levels

28-Jun-2017 - Vineti has developed a cloud-based software platform for creating and delivering cell and gene cell therapies, which the company says is better suited to high production loads than paper-driven processes.  ...

Lonza’s $5.5bn Capsugel takeover cleared by regulators

27-Jun-2017 - Lonza expects to complete its $5.5bn (€5.2bn) takeover of Capsugel SA in the next few days having secured approval from competition authorities around the world.

Repligen CEO says Spectrum acquisition fills gap in bioprocessing product line

27-Jun-2017 - Repligen Corporation has announced it will acquire filtration-focused Spectrum Pharmaceuticals for approximately $350m (€312m).

OSE Immunotherapeutics halts recruitment in cancer vaccine trial

27-Jun-2017 - OSE Immunotherapeutics SA has halted recruitment in a Phase III trial of its cancer vaccine Tedopi (OSE2101). 

US FDA rejects Pfizer's Epogen biosimilar citing McPherson site warning

23-Jun-2017 - Concerns about Pfizer’s fill/finish plant in McPherson, Kansas have prompted the US FDA to reject the firm’s biosimilar version of Amgen’s anaemia drug Epogen.

Protein A resin maker teams on continuous and column-free chromatography tech

23-Jun-2017 - ChromaTan will incorporate Purolite’s Protein A beads into its continuous platform in a move the firms say will up productivity by 15 times over conventional batch chromatography.

EMA committee gives Samsung Bioepis nod for Humira biosimilar Imraldi

23-Jun-2017 - The EMA has recommended the approval of Samsung Bioepis’ adalimumab biosimilar, placing the firm on the brink of having three anti-TNF inhibitors in Europe.

Takeda prepping to take over EU production of stem cell therapy from 2021

23-Jun-2017 - Takeda says it is assessing manufacturing options ahead of potential European approval later this year of the Crohn’s disease stem cell therapy licensed from TiGenix.

Cells held three times as long in 'delayed crosslinking' microgel tech

22-Jun-2017 - Dutch scientists have developed a microgel chip that is capable of holding single cells for analysis and research for far longer than currently available 3D culturing technologies.

ImmunoCellular Therapeutics halts brain cancer cell therapy trial due to lack of cash

22-Jun-2017 - ImmunoCellular Therapeutics Ltd has halted a Phase III trial of its brain cancer cell therapy ICT-107 due to a lack of funds and is looking for a buyer or partner...

Germany’s Merck invests in immune-oncology in Switzerland

21-Jun-2017 - Merck KGaA’s corporate venture division has created an immune-oncology company based on a mixture of small and large molecule drugs, including Merck and Pfizer’s Bavencio (avelumab). 

Brazilian plant to make Humira biosimilar in 'tobacco-based bioreactors'

21-Jun-2017 - A tobacco plant-based platform could make monoclonal antibodies up to 90% cheaper than mammalian systems, says Axis Biotec which is building a pilot plant in Brazil.

Ex-PM David Cameron tells BIO 2017 not to worry about Brexit effect on employees

21-Jun-2017 - Didn’t make it to San Diego this year? Well neither did we, but still we bring you the best BIO 2017 has to offer.

Patient deaths end Seattle Genetics leukaemia Phase III trial

21-Jun-2017 - Seattle Genetics announced it has discontinued its Phase III Cascade trial of Vadastuximab Talirine (SGN-CD33A) for the treatment of frontline acute myeloid leukaemia (AML), due to patient deaths.

TxCell hires Lentigen to make vectors used to produce its organ rejection cell therapy

20-Jun-2017 - TxCell SA has hired Lentigen Technology Inc. to make the vectors it uses to make its T-cell transplant rejection therapy.

Single-use in Ireland on the up? GE Healthcare, Thermo Fisher and NIBRT discuss the trend

20-Jun-2017 - Ireland’s “thriving biopharma industry ” has traditionally employed large-scale bioreactors, however a new wave of biologics with changing production requirements is changing the trend, say industry representatives.

Cell Medica buys T cell receptor cancer candidate from UK Catapult

20-Jun-2017 - Cell Medica says it will work with the Cell and Gene Therapy Catapult to assess automation and processing technologies involved in scaling-up the acquired cancer candidate.

Wuxi Biologics IPO in Hong Kong brings in $511m

16-Jun-2017 - Wuxi Biologics (Cayman) Inc. completed a successful IPO on the Hong Kong stock exchange on Tuesday, raising $511m.

Sanofi outlines €600m biologics manufacturing investment plan

16-Jun-2017 - Sanofi has said it will spend €600m ($673m) to increase capacity to make biologic drugs over the next three years.

Aimmune to make peanut allergy candidate in Florida, US

16-Jun-2017 - Aimmune Therapeutics has opened its commercial manufacturing facility in Florida, US, where it will manufacture its investigational peanut allergy treatment.

« Previous month Next month »

Key Industry Events

 

Access all events listing

Our events, Shows & Conferences...